Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

121. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine (...) if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. Design, Setting, and Participants: Patients (≥18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012

JAMA2017 Full Text: Link to full Text with Trip Pro

122. Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study.

Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. Objective To develop and externally validate risk prediction equations to estimate absolute and conditional survival in patients with colorectal cancer. Design Cohort study. Setting General practices in England providing data for the QResearch database linked to the national cancer registry. Participants 44 145 patients aged 15-99 with colorectal cancer from 947 (...) practices to derive the equations. The equations were validated in 15 214 patients with colorectal cancer from 305 different QResearch practices and 437 821 patients with colorectal cancer from the national cancer registry. Main outcome measures The primary outcome was all cause mortality and secondary outcome was colorectal cancer mortality. Methods Cause specific hazards models were used to predict risks of colorectal cancer mortality and other cause mortality accounting for competing risks

BMJ2017 Full Text: Link to full Text with Trip Pro

123. Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports 29114600 2018 11 13 2452-1094 2 3 2017 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports. 333-338 10.1016/j.adro.2017.06.001 Ebner Daniel K DK Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology, Chiba (...) 05 31 2017 06 01 2017 11 9 6 0 2017 11 9 6 0 2017 11 9 6 1 epublish 29114600 10.1016/j.adro.2017.06.001 S2452-1094(17)30101-X PMC5605310 J Immunother Cancer. 2016 Sep 20;4:51 27660705 Anticancer Res. 2007 Jan-Feb;27(1B):499-503 17348433 Nat Rev Clin Oncol. 2016 Aug;13(8):516-24 26951040 Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):293-5 22560555 Oncoimmunology. 2014 May 14;3:e28780 25083318 Cancer Lett. 2015 Jan 1;356(1):82-90 24125863 Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70

Advances in radiation oncology2017 Full Text: Link to full Text with Trip Pro

124. Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model 28649441 2018 11 13 2056-7189 3 2017 NPJ systems biology and applications NPJ Syst Biol Appl Clinical responses to ERK inhibition in BRAF V600E -mutant colorectal cancer predicted using a computational model. 14 10.1038/s41540-017-0016-1 Approximately 10% of colorectal cancers harbor BRAF V600E mutations, which constitutively activate the MAPK signaling pathway. We sought (...) to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) studies of cetuximab (EGFR), vemurafenib (BRAF), cobimetinib (MEK), and GDC-0994 (ERK) combinations. Preclinical data was used to develop a mechanism-based computational model linking cell surface receptor (EGFR) activation, the MAPK signaling pathway, and tumor growth. Clinical predictions of anti-tumor

NPJ systems biology and applications2017 Full Text: Link to full Text with Trip Pro

125. The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations

The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations Journals Library An error occurred retrieving (...) risk of colorectal cancer incidence. {{author}} {{($index , , , , , , , , , , , , , , , , , & . Wendy Atkin, 1 ,* Amy Brenner, 1 Jessica Martin, 1 Katherine Wooldrage, 1 Urvi Shah, 1 Fiona Lucas, 1 Paul Greliak, 1 Kevin Pack, 1 Ines Kralj-Hans, 1 Ann Thomson, 1 Sajith Perera, 1 Jill Wood, 1 Anne Miles, 2 Jane Wardle, 3 Benjamin Kearns, 4 Paul Tappenden, 4 Jonathan Myles, 5 Andrew Veitch, 6 Stephen W Duffy, 5 1 Cancer Screening and Prevention Research Group (CSPRG), Department of Surgery and Cancer

NIHR HTA programme2017

126. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial

What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404 (...) ) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Single CEA tests for triage in follow-up of colorectal cancer generate many false positives and are less clinically useful than CEA trends. {{author}} {{($index , , , , , , & . Bethany Shinkins, 1 Brian D Nicholson, 1 Tim James, 2 Indika Pathiraja, 1

NIHR HTA programme2017

127. Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial

Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial 28505217 2017 05 15 2017 05 15 2168-6114 2017 May 15 JAMA internal medicine JAMA Intern Med Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial. 10.1001/jamainternmed.2017.1294 Colorectal cancer (CRC (...) of North Carolina School of Medicine, Chapel Hill3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill. Brenner Alison T AT Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill2Division of General Medicine & Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill3Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill. Hoffman Richard R Department of Medicine, University of Iowa

EvidenceUpdates2017

128. Racial and Ethnic Disparities in Interval Colorectal Cancer Incidence: A Population-Based Cohort Study.

Racial and Ethnic Disparities in Interval Colorectal Cancer Incidence: A Population-Based Cohort Study. Background: Interval colorectal cancer (CRC) accounts for 3% to 8% of all cases of CRC in the United States. Data on interval CRC by race/ethnicity are scant. Objective: To examine whether risk for interval CRC among Medicare patients differs by race/ethnicity and whether this potential variation is accounted for by differences in the quality of colonoscopy, as measured by physicians' polyp (...) [CI, 1.25 to 2.31]) and distal colon (HR, 1.45 [CI, 1.00 to 2.11]) than for cancer of the proximal colon (HR, 1.17 [CI, 0.96 to 1.42]). Adjustment for PDR did not alter HRs by race/ethnicity, but differences between black persons and white persons were greater among physicians with higher PDRs. Limitation: Colonoscopy and polypectomy were identified by using billing codes. Conclusion: Among elderly Medicare enrollees, the risk for interval CRC was higher in black persons than in white persons

Annals of Internal Medicine2017 Full Text: Link to full Text with Trip Pro

129. Endoscopic treatment for high-risk T1 colorectal cancer: is it better to begin with endoscopic or surgical treatment?

Endoscopic treatment for high-risk T1 colorectal cancer: is it better to begin with endoscopic or surgical treatment? 28529993 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Endoscopic treatment for high-risk T1 colorectal cancer: is it better to begin with endoscopic or surgical treatment? 39 10.21037/tgh.2017.04.04 Fujihara Shintaro S Department of Gastroenterology, Kagawa Rousai Hospital, Japan. Mori Hirohito H Departments (...) Gastroenterol. 2017 Feb 13;:null 28194526 Gastroenterology. 2013 Mar;144(3):551-9; quiz e14 23232297 Dig Endosc. 2013 May;25 Suppl 2:6-10 23617641 Dig Endosc. 2011 Apr;23(2):190-4 21429028 Int J Clin Oncol. 2012 Feb;17(1):1-29 22002491 Gastrointest Endosc. 2014 Jun;79(6):951-60 24412574 Endoscopy. 2013 Sep;45(9):718-24 23918621 Int J Colorectal Dis. 2016 Mar;31(3):571-8 26689400 Gastroenterology. 2014 Aug;147(2):278-80.e1 24973723 Endoscopy. 2015 Aug;47(8):719-25 25763833 Biomed Res Int. 2014;2014:925058

Translational gastroenterology and hepatology2017 Full Text: Link to full Text with Trip Pro

130. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer 28761750 2018 11 13 2059-7029 2 2 2017 ESMO open ESMO Open European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. e000190 10.1136/esmoopen-2017-000190 On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap (...) ) in combination with irinotecan/5-fluorouracil/folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer resistant to or progressive after an oxaliplatin-containing regimen. Aflibercept is a recombinant fusion protein which blocks the activation of vascular endothelial growth factor (VEGF) receptors and the proliferation of endothelial cells, acting as a soluble decoy receptor that binds to VEGF-A with higher affinity than its native receptors, as well as placental growth factor

ESMO open2017 Full Text: Link to full Text with Trip Pro

131. Trifluridine/tipiracil (colorectal cancer): Addendum to Commission A16-54

Trifluridine/tipiracil (colorectal cancer): Addendum to Commission A16-54 Trifluridin/Tipiracil (Kolorektalkarzinom): Addendum zum Auftrag A16-54; Auftrag A16-77 [Trifluridine/tipiracil (colorectal cancer): Addendum to Commission A16-54] Trifluridin/Tipiracil (Kolorektalkarzinom): Addendum zum Auftrag A16-54; Auftrag A16-77 [Trifluridine/tipiracil (colorectal cancer): Addendum to Commission A16-54] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Trifluridin/Tipiracil (Kolorektalkarzinom): Addendum zum Auftrag A16-54; Auftrag A16-77. [Trifluridine/tipiracil (colorectal cancer): Addendum to Commission A16-54] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

Health Technology Assessment (HTA) Database.2017

132. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer

Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer 27769517 2016 10 22 2017 03 27 1528-0012 152 5 2017 Apr Gastroenterology Gastroenterology Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. 1217-1237.e3 S0016-5085(16)35025-9 10.1053/j.gastro.2016.08.053 The use of the fecal (...) occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative

EvidenceUpdates2017

133. Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. Importance: The fecal immunochemical test (FIT) is commonly used for colorectal cancer screening and positive test results require follow-up colonoscopy. However, follow-up intervals vary, which may result in neoplastic progression. Objective: To evaluate time to colonoscopy after a positive FIT result and its association with risk of colorectal cancer (...) and advanced-stage disease at diagnosis. Design, Setting, and Participants: Retrospective cohort study (January 1, 2010-December 31, 2014) within Kaiser Permanente Northern and Southern California. Participants were 70 124 patients aged 50 through 70 years eligible for colorectal cancer screening with a positive FIT result who had a follow-up colonoscopy. Exposures: Time (days) to colonoscopy after a positive FIT result. Main Outcomes and Measures: Risk of any colorectal cancer and advanced-stage disease

JAMA2017

134. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)

Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM) 28761730 2018 11 13 2059-7029 2 1 2017 ESMO open ESMO Open Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). e000147 10.1136/esmoopen-2016-000147 In the past 15 years, the outcome for patients with metastatic colorectal cancer has substantially improved owing to the availability of new cytotoxic and biological agents (...) in the management of patients with metastatic colorectal cancer in their daily clinical practice. Salvatore Lisa L Department of Oncology, Azienda Ospedaliero-Universitaria Integrata di Verona, Verona, Italy. Aprile Giuseppe G Department of Oncology, Ospedale San Bortolo, Vicenza, Italy. Arnoldi Ermenegildo E Department of Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. Aschele Carlo C Department of Oncology, ASL5 Liguria, La Spezia, Italy. Carnaghi Carlo C Department of Oncology, Humanitas

ESMO open2017 Full Text: Link to full Text with Trip Pro

135. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer Cetuximab and panitumumab for Cetuximab and panitumumab for pre previously untreated metastatic viously untreated metastatic colorectal cancer colorectal cancer T echnology appraisal guidance Published: 29 March 2017 nice.org.uk/guidance/ta439 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

National Institute for Health and Clinical Excellence - Technology Appraisals2017

136. Ramucirumab (colorectal cancer)

Ramucirumab (colorectal cancer) 1 Translation of addendum A16-10 Ramucirumab (Kolorektalkarzinom) – Addendum zum Auftrag A16-10 (Version 1.0; Status: 27 July 2016). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 27 July 2016 1.0 Commission: A16-50 Version: Status: IQWiG Reports – Commission No. A16-50 Ramucirumab (colorectal cancer) – Addendum (...) to Commission A16-10 1 Addendum A16-50 Version 1.0 Ramucirumab (colorectal cancer) – Addendum to Commission A16-10 27 July 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ramucirumab (colorectal cancer) – Addendum to Commission A16-10 Commissioning agency: Federal Joint Committee Commission awarded on: 15 July 2016 Internal Commission No.: A16-50 Address of publisher: Institut für Qualität und

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

137. Predictors of primary care provider adoption of CT colonography for colorectal cancer screening

Predictors of primary care provider adoption of CT colonography for colorectal cancer screening 27864601 2018 03 26 2018 12 02 2366-0058 42 4 2017 04 Abdominal radiology (New York) Abdom Radiol (NY) Predictors of primary care provider adoption of CT colonography for colorectal cancer screening. 1268-1275 10.1007/s00261-016-0971-9 To examine factors influencing primary care provider (PCP) adoption of CT colonography (CTC) for colorectal cancer (CRC) screening. We performed a retrospective cohort (...) Abdom Radiol (NY) 101674571 IM Adult Aged Colonography, Computed Tomographic statistics & numerical data Colorectal Neoplasms diagnostic imaging Early Detection of Cancer Female Humans Male Mass Screening methods Medical Record Linkage Middle Aged Practice Patterns, Physicians' statistics & numerical data Primary Health Care Retrospective Studies CT colonography Colorectal cancer screening Primary care providers 2016 11 20 6 0 2018 3 27 6 0 2016 11 20 6 0 ppublish 27864601 10.1007/s00261-016-0971-9

Abdominal radiology (New York)2017 Full Text: Link to full Text with Trip Pro

138. The necessity of colorectal cancer screening for elderly patients

The necessity of colorectal cancer screening for elderly patients 28447054 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol The necessity of colorectal cancer screening for elderly patients. 19 10.21037/tgh.2017.03.03 Kudo Shin-Ei SE Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan. Kudo Toyoki T Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan. eng Editorial Comment

Translational gastroenterology and hepatology2017 Full Text: Link to full Text with Trip Pro

139. What is the optimal colorectal cancer screening program for an average-risk population?

What is the optimal colorectal cancer screening program for an average-risk population? 28447052 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol What is the optimal colorectal cancer screening program for an average-risk population? 17 10.21037/tgh.2017.03.05 Sekiguchi Masau M Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan. Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan. Division of Screening (...) Technology, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. Matsuda Takahisa T Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan. Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan. Division of Screening Technology, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan. Saito Yutaka Y Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan. eng Editorial Comment 2017 03 16 China Transl Gastroenterol Hepatol 101683450

Translational gastroenterology and hepatology2017 Full Text: Link to full Text with Trip Pro

140. Cavernous sinus syndrome associated with metastatic colorectal cancer and perineural spread along the trigeminal nerve

Cavernous sinus syndrome associated with metastatic colorectal cancer and perineural spread along the trigeminal nerve 29260062 2018 11 13 2451-9936 6 2017 Jun American journal of ophthalmology case reports Am J Ophthalmol Case Rep Cavernous sinus syndrome associated with metastatic colorectal cancer and perineural spread along the trigeminal nerve. 67-70 10.1016/j.ajoc.2016.11.011 We report the case of a patient with cavernous sinus syndrome associated with biopsy-confirmed metastasis from (...) colorectal cancer. A patient known for laryngeal carcinoma and metastatic colorectal carcinoma presented with symptoms of left trigeminal neuralgia and progressive, near-complete ophthalmoplegia. Magnetic resonance imaging (MRI) revealed a mass in the left cavernous sinus, extending into Meckel's cave with perineural spread along the mandibular branch of the left trigeminal nerve. A transsphenoidal biopsy was performed and demonstrated metastatic colon adenocarcinoma. We review the existing literature

American journal of ophthalmology case reports2017 Full Text: Link to full Text with Trip Pro